Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025
Rhea-AI Summary
Pacira BioSciences (Nasdaq: PCRX), a leader in non-opioid pain therapies, has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, after U.S. markets close.
Key details:
- Conference Call Time: 4:30 p.m. ET
- Participation Options: Live conference call and webcast
- Access Method: Pre-registration required for Q&A telephone participation
- Alternative Access: Live audio webcast available through "Events" page on investor.pacira.com
- Replay Availability: Webcast recording accessible for approximately two weeks post-call
Positive
- Company maintains its position as industry leader in non-opioid pain therapies
Negative
- None.
News Market Reaction
On the day this news was published, PCRX declined 0.52%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
BRISBANE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its first quarter financial results after the close of the U.S. markets on Thursday May 8, 2025. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET.
For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the “Events” page on the Pacira website at investor.pacira.com. For those unable to participate in the live call, a replay of the webcast will be available on the Pacira website for approximately two weeks following the call.
About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.
Investor Contact: Pacira BioSciences, Inc. Christian Pedetti, (973) 254-4387 Christian.Pedetti@pacira.com
FAQ
When will Pacira (PCRX) release Q1 2025 earnings?
How can investors join Pacira's (PCRX) Q1 2025 earnings call?
What time is Pacira's (PCRX) Q1 2025 earnings conference call?
How long will Pacira's (PCRX) Q1 2025 earnings call replay be available?
Where can I find Pacira's (PCRX) Q1 2025 earnings webcast?
